Ginny Powers, PhD

Position title: Project Manager, Catalent Pharma Solutions, Madison, WI


Phone: Advisor: Dr. Elaine Alarid

Graduation: 01/2012

Ginny Powers


  • Lang JD, Berry SM, Powers GL, Beebe DJ, Alarid ET (2013). Hormonally responsive breast cancer cells in a microfluidic co-culture model as a sensor of microenvironmental activity. Integr Biol (Camb). 5:807-816. PMID: 23559098 [PubMed – in process]
  • Powers GL, Rajbhandari P, Solodin NM, and Alarid ET (2013). Bortezomib represses ERαgene expression by modifying chromatin at a distal enhancer.Molecular Pharmacology. (Submitted)
  • Powers GL and Marker PC (2013). Recent advances in prostate development and links to prostatic diseases. Wiley Interdiscip Rev Syst Biol Med. 5:243-256. Epub 2013 Jan 17. Review. PMID: 23335485 [PubMed – indexed for MEDLINE]
  • Powers GL, Ellison-Zelski SJ, Casa AJ, Lee AV, and Alarid ET (2009).Proteasome inhibition represses ERalpha gene expression in ER+ cells: a new link between proteasome activity and estrogen signaling in breast cancer. Oncogene. 29:1509-18. PMCID: PMC2837136
  • Valley CC, Solodin NM, Powers GL, Ellison SJ, and Alarid ET (2008). Temporal variation in estrogen receptor-alpha protein turnover in the presence of estrogen.J Mol Endocrinol. 40:23-34. PMID: 18096994